Inclusion Criteria:

1. Suspected preoperative diagnosis of invasive epithelial ovarian cancer, primary
peritoneal carcinoma, fallopian tube cancer based on imaging and Ca 125. Histologic
epithelial cell types are eligible: serous adenocarcinoma, endometrioid
adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell
carcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified. The
surgically confirmed histologic features must be compatible with primary Müllerian
epithelial adenocarcinoma

2. Stages II-IV of the above cancer

3. Patients to be scheduled for a planned tumor debulking

4. Intention for chemotherapy administration at MD Anderson Cancer Center

5. Zubrod performance status 0-2

6. Patients must have adequate: (a) Bone marrow function: Absolute neutrophil count
(ANC) >/=1500/ml. (b) Platelets >100,000/mL. (c) Renal function: Creatinine clearance
(CrCl) > 50 mL/min. (d) Hepatic function: Bilirubin limit normal; SGOT and alkaline phosphatase normal. (e) Neurologic function: Neuropathy (sensory and motor) to Common Toxicity Criteria for Adverse Events version 3 (CTCAE). (f) Blood
coagulation parameters: PT such that international normalized ratio (INR) is (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of
therapeutic warfarin for the management of venous thrombosis including pulmonary
embolus) and a PTT <1.2 times institutional upper limit of normal.

7. (CONTINUED FROM NO. 6) Patient must have adequate: (g) Hemodynamics: Pulse >/= 60
beat per minute (bpm); Systolic blood pressure (SBP) > 110 mmHg; diastolic blood
pressure (DBP) >/= 60 mmHg. (h) Normotensive individuals not already on beta blockers
(may be on other anti hypertensives): SBP
8. Surgery or neoadjuvant chemotherapy must be scheduled at least 72 hours in advance in
order for the patient to take at least 48 hours of prescribed Propranolol and have
stable vital signs confirmed.

9. An approved informed consent and authorization permitting release of personal health
information must be signed by patient or guardian.

10. Age >/= 18 years at MDACC and age >/= 18 to < /= 64 at LBJ

11. Patients of childbearing age must have a negative pregnancy test.

12. Patients who receive neoadjuvant chemotherapy for their ovarian, primary peritoneal,
or fallopian tube cancer

Exclusion Criteria:

1. Patients with non-epithelial ovarian tumors that do not require adjuvant
chemotherapy, borderline epithelial ovarian tumor, or recurrent invasive epithelial
ovarian, low grade ovarian cancer, primary peritoneal, or fallopian tube cancer
treated with surgery only (such as patients with stage IA or IB). Patients with a
prior diagnosis of a borderline tumor that was surgically resected and who
subsequently develop an unrelated new invasive epithelial ovarian, primary
peritoneal, or fallopian tube cancer are eligible, provided that they have not
received chemotherapy for any tumor. Patients found post operatively to have
ineligible histology will be removed from the study.

2. Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis are excluded. Prior radiation therapy for localized cancer of the breast,
head and neck, or skin is permitted provided that it was completed more than 3 years
prior to registration, and the patient remains free of recurrent or metastatic
disease.

3. Patients with a synchronous primary endometrial cancer, or a past history of primary
endometrial cancer are excluded unless all of the following conditions are met: stage
not greater than stage IA; no more than superficial myometrial invasion, without
vascular or lymphatic invasion; no poorly differentiated subtypes, including
papillary serous, clear cell, or other FIGO grade 3 lesions.

4. Patients who have received targeted therapy (including but not limited to vaccines,
antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their
primary peritoneal, ovarian, or fallopian tube cancer.

5. With the exception of non-melanoma skin cancer and other specific malignancies as
noted above, patients with other invasive malignancies who had (or have) any evidence
of the other cancer present with the last five years or whose previous cancer
treatment contraindicates this protocol therapy are excluded.

6. Metastases to the ovaries from other organs except fallopian tube or primary
peritoneal carcinoma

7. Use of systemic glucocorticoids such as Prednisone or Decadron in the last month

8. Inability to accurately answer questions (e.g. dementia, brain metastases) or speak
English or Spanish

9. Cirrhosis of the liver

10. Patients with a Zubrod Performance status 3 or 4

11. Age < 18 years at MDACC and age < /= 18 to >/= 65 at LBJ

12. Comorbid conditions: Addison's disease, autoimmune hepatitis, hepatitis B, hepatitis
C, AIDS or HIV, lupus erythematosus, mixed connective tissue disease, rheumatoid
arthritis.

13. Any patients already on beta-blockers or contraindicated to receive beta-blockers.

14. Hypersensitivity to propranolol, or beta-blockers

15. Uncompensated congestive heart failure

16. Cardiogenic shock

17. Severe sinus bradycardia; heart block, second or third degree or sick sinus syndrome
(if no artificial pacemaker present)

18. Severe hyperactive airway disease (chronic obstructive pulmonary disease, asthma)

19. Any patients planning to receive Avastin or any other anti-angiogenic drugs.

20. Patients with brittle diabetes mellitus (DM). Brittle diabetes mellitus is a type of
diabetes when a person's blood glucose (sugar) level often swings quickly from high
to low and from low to high. Also called "unstable diabetes" or "labile diabetes."